{
    "nct_id": "NCT04965311",
    "official_title": "A Phase II Trial of Pre-Operative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy",
    "inclusion_criteria": "* Participant scheduled for elective distal pancreatectomy or radical antegrade modular pancreatosplenectomy (RAMPS), via open or laparoscopic technique\n* Participant >= 18 years of age\n* Ability to understand nature and individual consequences of clinical trial\n* Written informed consent from participant or legally authorized representative\n* For participants of childbearing potential, a negative pregnancy test and adequate contraception until 14 days after trial intervention\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known hypersensitivity to any BTX preparation or to any of the components in the formulation\n* Infection at the proposed injection site, including cholangitis\n* Anatomy incompatible with planned intervention (e.g., Roux-en-Y gastric bypass, distal gastrectomy with Roux-en-Y or Billroth II reconstruction)\n* Acute pancreatitis within 2 weeks of planned study intervention\n* American Society of Anesthesiologists (ASA) score > III\n* Serious cardiovascular disease (e.g., myocardial infarction in the past year, New York Heart Association [NYHA] III/IV congestive heart failure, unstable angina)\n* Creatinine clearance < 30 mL/min\n* Liver cirrhosis (of any Child-Pugh grade)\n* Neuromuscular or any neurological disease with associated increased risk for a participant undergoing BTX injection\n* Prior BTX administration\n* Inability to obtain informed consent due to comprehension or language barrier\n* Inability to comply with study and/or follow-up procedures\n* Pregnancy or lactation\n* Any condition that could result in undue risk for the participant and/or influence outcome measures (in the opinion of the investigator)",
    "miscellaneous_criteria": ""
}